Quote:

---

Ohm if you read this. What’s your thoughts as to what could be so urgent about the actual data? My guess is maybe CTC almost completely stop growing and maybe huge reductions in metastasis. Maybe the overall survival data that we never got an update on will be in this publication?

All the sudden communication was cut completely short when we requested BTD on TNBC, that is if I’m remembering this correctly. We were all wondering how far free progression survival rate went out with CD07. I believe the excuse is we didn’t have that actual data past 12 months. Is that true still to this day?

---

I am waiting for the actual data. The way they expressed it as percentages in the press releases was quite annoying. We know median overall survival was 12+ months compared to 11.8 for Trodolvey. How much over 12 months we should find out in the peer reviewed paper.

My guess is at some point Amarex refused to give further data including mOS to Cytodyn. The primary and secondary endpoints would have been tracked for up to 2 years. It's expressed as up to 2 years because there is a possibility that all patients might be deceased before that time. Amarex would have definitely been tracking that data because it relates to safety and if they didn't track safety data the FDA could completely shut down Amarex.

Of course when we sued them for all the data files and won we got all the raw data from the mTNBC trial. It would take a bit of time to compile and analyze it which must have been done if they're going to release a peer reviewed paper. This time it will have been done up to standard. The results must be excellent if they're exciting management.